Form 4: Jason Aryeh Acquires Shares in Lifecore Biomedical Through Restricted Stock Units

Director Jason Aryeh acquired 24,554 shares of Lifecore Biomedical through restricted stock units that vest in 2025.

Summary

• On August 19, 2024, Jason Aryeh, a director of Lifecore Biomedical, Inc., acquired 24,554 shares of common stock.
• The acquisition was through restricted stock units (RSUs) that convert into common stock on a 1-for-1 basis.
• These RSUs vest on the earlier of July 8, 2025, or the date of the annual meeting of stockholders first held in calendar year 2025, provided it's no less than 50 weeks from July 8, 2024.
• Following the transaction, Aryeh directly owns 24,554 shares of Lifecore Biomedical.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (stock units vesting) and insider confidence, but it's not a major event.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units in 2025 will result in the issuance of common stock to Jason Aryeh.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's stock. This filing indicates a director's acquisition of shares, which is a common occurrence.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of shares held by a director, potentially aligning his interests with theirs.

Key Dates